You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • Correction: Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

https://doi.org/10.1136/jitc-2022-004952corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Han X, Tang X, Zhu H, et al. Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. Journal for ImmunoTherapy of Cancer 2022;10:e004952. doi: 10.1136/jitc-2022-004952

    The graphic symbol in the PFS curve on the left of figure 4C was incorrect. It now reads 'red for ctDNA clear' and 'blue for ctDNA residual'.